Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
Wednesday, 31 October 2012
Pressure Biosciences "banging at the door" of life sciences market, Seraphim says
Pressure BioSciences (OTCQB:PBIO) recently received a favourable mention by Seraphim Strategies on its Tomorrow's Bluechips site.
Pressure BioSciences is a life science, medical device company that developments and commercializes pressure cycling technology (PCT) which uses instrumentation that cycles pressure between ambient and ultra-high levels at controlled temperatures to control the interactions of bio-molecules.
PBIO's technology is used for genomic, proteomic, and small molecule sample preparation as well used by scientists in a variety of areas, including human cancer and other diseases, soil and plant biology, vaccine development, mass spectrometry, and even counter-bioterror research.
"With a long-standing reputation in the life sciences community as a company committed to the advancement of sample preparation and molecular biology research, Pressure BioSciences has resurfaced in the last year with an abundance of activity, and investors in the biosciences industry should take note," Seraphim Strategies said, adding that at current levels, the stock "should be considered, at the very least, a tremendously undervalued investment."
According to Pressure BioSciences' CEO Richard T. Schumacher, the company's Barocycler machines can safely reach pressure levels several times greater than those found at the deepest levels of any ocean, making Pressure BioSciences the first company to ever harness this technology in a laboratory and market it as instruments and consumables.
"And with their strong portfolio of 24 issued patents, they just may be the only company to do so well into the future," Seraphim Strategies said.
Based on the success of this powerful technology, as well as grants totaling nearly a million dollars over the course of the past year, in August the company reported 70 per cent growth in revenue for the second straight quarter.
Seraphim notes that perhaps the most exciting area of discovery for consumers of PCT technology, however, is that of forensics.
In mid-October, after extensive studies of PCT technology within the application of forensic DNA analysis, the Harris County Institute of Forensic Sciences in Houston, Texas, as well as the Institute of Applied Genetics at the University of North Texas Health Science Center (UNT) both concluded that PCT can significantly enhance the accuracy of DNA sample results.
"We consider our study as a proof of concept that PCT treatment might be a viable method to overcome certain inhibitory effects that can adversely affect DNA testing," said Dr. Bruce Budowle of the Institute of Applied Genetics at UNT.
"Importantly, it appears that PCT can reduce the effects of inhibitors known to be present in some bone samples, resulting in a marked improvement in DNA testing of these often difficult samples."
Seraphim concluded: "Shareholders looking for a tried and true investment into a significantly undervalued company run by a guy who has had three prior major successes for a relatively small amount of capital need look no further than PBIO."